The Subject Expert Committee (SEC) of the Drug Controller General of Indi (DCGI) recommended made in India Corbevax for children between the age group of 5 years old to 12 years old in India.
On the 21st of April, Thursday, the Government formed SEC advised the emergency use authorisation (EUA.) The panel held a meeting and discussed the approval of the Biological E’s Corbevax. After the meeting, the panel submitted a detailed report to the DCGI for approval.
A nod by the DCGI is now awaited before the Union Health Ministry gives a final go ahead.
It is to be noted, that the vaccine, Corbevax is currently being administered to children in the age group 12-14 years. Furthermore, the SEC approval came at a time when India is witnessing a spike in the Wuhan Virus cases are increasing in India. It is to be noted, in the past 24 hours, India reported 2,451 new Wuhan virus infections, taking the overall tally to 4,30,52,425, while the active cases increased to 14,241.
It is to be noted, that India is currently administering two Wuhan Virus vaccines, one is Corbevax and another is the Bharat Biotech Private Limited manufactured Covaxin to children above 12 years of age.
If approved by the DCGI and the Union Health Ministry, the vaccine would begin for children between 5 years old to 12 years old in India.
Stay tuned for further updates.
Mango News Link
Telegram: https://t.me/mangonewsofficial
Google Play Store: https://bit.ly/2R4cbgN
Apple / iOS Store: https://apple.co/2xEYFJ
Subscribe to our email newsletter to get the latest posts delivered right to your email.
Comments